Human Microbiome Market
Number of pages: 100 | Report Format: PDF | Published date: October 31, 2022
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 74.21 billion |
|
Revenue Forecast in 2031 |
US$ 552.92 billion |
|
Growth Rate |
CAGR of 25.0% from 2023-2031 |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2021 |
|
Segments Covered |
Product, Disease, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global companion animal diagnostics market was valued at US$ 74.21 billion in 2022 and is expected to register a revenue CAGR of 25.0% to reach US$ 552.92 billion by 2031.
Human Microbiome Market Fundamentals
The human microbiome is the collection of all microbiotas that live on or within human tissues and biofluids, as well as the anatomical sites which include the skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary tract, and gastrointestinal tract. Bacteria, archaea, fungi, protists, and viruses are all examples of the human microbiota. The phrase "human microbiome" is occasionally used in genomics to refer to the aggregate genomes of resident bacteria.
Firmicutes, Bacteroidetes, and Actinobacteria are the three primary phyla that comprise the varied gut microbiota. This rich and complex microbiome functions as a functional extension of host genomes, containing 50- to 100-fold more genes than the host. These additional genes have introduced numerous types of enzyme proteins that were not encoded by the host and serve a crucial function in enabling host metabolism, therefore contributing to host physiological control. The properties of the human microbiome and host-microbiota interactions were largely unknown until recently due to technological limitations, particularly in examining non-cultivable microbes of interest, and a lack of population-scale data depicting microbiota compositions and functions.
The human microbiome is crucial to contemporary healthcare because it performs various tasks, including facilitating simple digestion of food, controlling immunological function, and producing vitamins, including Vitamin K, Vitamin B, and Vitamin B12. The human microbiome improves immunity and supplies essential nourishment. According to an article published in the International Journal of Microbiology on May 22, 2020, the human microbiome has recently attracted significant attention due to its connections to several respiratory illnesses and immunity. A person's immunity has been linked to their gut microbiome.
[54344232]
Human Microbiome Market Dynamics
Applications of microbiome technology in human health are responsible for the global human microbiome market's positive growth. Predictive, preventative, and personalized medicine are among the major uses of the microbiome. In addition, industry mergers and acquisitions and strategic alliances are fostering market expansion. For instance, in February 2021, DuPont's Nutrition and Biosciences division announced a merger with International Flavors & Fragrances.
One of the main reasons driving the market growth is the rising prevalence of chronic lifestyle illnesses and infections caused by microbial dysbiosis worldwide. The aging population, which is more vulnerable to these diseases, is also driving market expansion. The market's growth can also be attributable to the increased focus on developing medicines for the human microbiome that are more effective. To effectively treat a variety of gastrointestinal disorders, the human gut microbiota is being cultivated in precise combinations. In keeping with this, the start of the coronavirus (COVID-19) pandemic is also boosting market expansion. Researchers are deeply examining the lung microbiomes to evaluate the severity of the illnesses and create the necessary treatments and vaccinations.
However, increasing regulatory regulations over microbiome-based medicines will hinder the global human microbiome market's expansion. Because microbiome-based treatments are a novel idea, there are certain safety concerns. There is currently an insufficient standard regulatory framework for microbiome-based pharmaceuticals. Strong evidence-based research on the safety of giving live bacteria or bacterial products to the human body is necessary. There are also some reservations regarding the effectiveness of the microbiome-based platform. Identifying a relationship between microbiome dysbiosis and illness is crucial for determining the clinical potential of the human microbiome market. The absence of consistency in the microbiome in the intended patient pool may impact clinical trial outcomes, posing a unique set of issues for clinical trial design.
Human Microbiome Market Ecosystem
The global human microbiome market has been analyzed from the following perspectives: product, disease, application, and region.
Human Microbiome Market by Product
[8391283]
Based on product, the global human microbiome market is segmented into probiotics, prebiotics, drugs, medical food, and others.
The probiotics segment is likely to dominate the market. The market is being driven by the rising consumer preference for preventative healthcare and the discovery of effective probiotic strains. Probiotics benefit the body when consumed in sufficient quantities, such as better gut health and reduced intestinal inflammation. Probiotics play an important role in preventive healthcare since they improve the immune system and help avoid illness. As a result, increased awareness about preventive healthcare will likely drive market growth throughout the forecast period.
Human Microbiome Market by Disease
Based on disease, the global human microbiome market is segmented into obesity and diabetes, autoimmune disorders, cancer, gastrointestinal disorders, endocrine & disorders, and others.
The market for the human microbiome is increasing as the prevalence of lifestyle illnesses such as cancer and diabetes rises. The obesity segment is predicted to have the greatest share of the market, while the diabetes segment is expected to grow at the fastest rate throughout the forecast period.
Human Microbiome Market by Application
The global human microbiome market is segmented based on application into therapeutics and diagnostics.
During the projection period, microbiome therapeutics have a wide range of uses in COVID-19, IBD, C. difficile infections, Crohn's disease, and diabetes. Growing research efforts done by research institutions and market participants to uncover additional therapeutic uses of the human microbiome and the growing illness burden are all contributing to the segmental growth.
The growing number of research studies will likely drive the market segment's growth. According to clinical trials.gov, the University of Zurich studied the microbiome in COVID-19 patients for future preventative and therapeutic approaches (MICRO-COV). The research began in April 2020 and is projected to be finished in December 2023. Positive findings from such investigations might lead to the development of new products and services.
Human Microbiome Market by Region
The global human microbiome market has been segmented based on region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America held the largest share and dominated the market. This region's market growth is fueled by the presence of several highly sophisticated healthcare facilities and rising investment from the main healthcare providers. According to the Centre for Medicare & Medicaid Services, the cost of health care in the U.S. increased by 9.7% in 2020, reaching a whopping USD 4.1 trillion, or USD 12,530 per person. Additionally, the USA's health spending made up 19.7% of the entire Gross Domestic Product of the country.
Furthermore, rising research studies and regulatory authority assistance for the inquiry are adding to the region's market expansion. For example, 4D Pharma Plc gained FDA approval in February 2022 for investigational new drug (IND) applications for two Live Biotherapeutics, MRx0005, and MRx0029, to treat Parkinson's disease. Such approvals are likely to fuel market expansion.
Europe is likely to increase its market share during the forecast period as a result of extensive research and development of novel human microbiome applications. According to NCBI, new microbiome programs such as ONCOBIOME, MICROB-predict, and GEMMA focus on cancer, human microbiota mapping, and autistic spectrum disorders, respectively. They are expected to boost market expansion in this area in March 2020.
Furthermore, Asia Pacific is predicted to develop during the forecast period because of the increased creation of microbiome and ancillary fields. For instance, the Institute of Genomics and Integrative Biology (IGIB), a CSIR institute, will lead the Genomics for Public Health in India, popularly known as the IndiGen project, in March 2020. It intends to enroll 20,000 Indians in genome sequencing over the next few years to establish a larger database. The data will be critical in developing know-how, baseline data, and indigenous competence in the rising field of precision medicine.
Human Microbiome Competitive Landscape
The human microbiome market is slightly competitive, with several firms developing novel products. Companies typically use strategies like new product launches and mergers and acquisitions to extend their global footprints and product portfolio. Companies in the human microbiome market rely on collaborative strategies to expand their clientele, which allows them to keep their brand identity globally. Some of the prominent players in the global human microbiome market include
Human Microbiome Strategic Development
The estimated market size of the human microbiome industry in 2031 will be US$ 552.92 billion.
The revenue CAGR of the human microbiome market during the forecast period will be 25.0%.
Some prominent players in the global human microbiome market include OBiome, Enterome Biosciences SA, and 4D Pharma.
The therapeutics segment dominated the global human microbiome market.
The market for microbiomes globally is still developing. Therefore, the possibility of adverse clinical trial outcomes is a risk that can limit market expansion.
*Insights on financial performance is subject to the availability of information in the public domain
Recommended Reports